Crystalloid fluids are a subset of intravenous solutions that find frequent use in the clinical setting. Crystalloid fluids are the first-line choice for fluid resuscitation in the presence of hypovolemia, hemorrhage, sepsis, and dehydration. Further clinical applications include acting as a solution for intravenous medication delivery, to deliver maintenance fluid in patients with limited or no enteral nutrition, blood pressure management, and to increase diuresis to avoid nephrotoxic drug or toxin-mediated end-organ damage.
While normal saline (0.9% NaCl Solution) is the most frequently used crystalloid fluid, many other formulations can provide improved clinical outcomes in specific patient populations.
Other commercially available crystalloid fluids include:
A crystalloid fluid is an aqueous solution of mineral salts and other small, water-soluble molecules. Most commercially available crystalloid solutions are isotonic to human plasma. These fluids approximate concentrations of various solutes found in plasma and do not exert an osmotic effect in vivo. Crystalloid fluids function to expand intravascular volume without disturbing ion concentration or causing large fluid shifts between intracellular, intravascular, and interstitial spaces.
Hypertonic solutions such as 3% saline solutions contain higher concentrations of solutes than those found in human serum. Because of this discrepancy in concentration, these fluids are osmotically active and therefore will cause fluid shifts. Their primary indication is for emergent replacement of serum solutes, such as in hyponatremia with neurologic symptoms.
Buffered solutions contain molecules that metabolize in vivo to bicarbonate. These solutions were designed to sustain a normal physiologic plasma pH. The three commonly used molecules are lactate, acetate, and gluconate. Lactate and gluconate are hepatically metabolized to bicarbonate while acetate is predominantly metabolized peripherally by skeletal muscle.
Crystalloid fluids are administered parenterally via an intravenous infusion. Infusion rates depend on the clinical presentation and indication for administration.
In an acute setting, rapid infusion of crystalloid fluids may be indicated. In this setting, it may require a pressure apparatus to the bag of fluid to achieve a higher infusion rate. In this clinical setting, larger bore intravenous cannulas should be used to ensure safe administration of high fluid volumes. Fluids should be administered preferably via large-bore peripheral lines (18-gauge or larger) or through a central access, which may also be used for delivery of blood products if required.
In 2012, the Surviving Sepsis Campaign guidelines recommended Early Goal-directed therapy (EGDT) as the standard of care in managing patients in septic shock. These guidelines dictated that patients receive empirically dosed rapid volume resuscitation. Patients should receive a fluid challenge of 20 mL/kg over the first 30 minutes of treatment. Subsequent volume dosing should depend on the severity of hypovolemia and should be adjusted in increments of 500 mL, aiming for an ultimate central venous pressure of 8-12 mmHg. However, revised guidelines in 2018 have called into question the efficacy of EGDT. The revised guidelines now state that fluid provision should be in a 1-hour bundle by administering 30 mL/kg crystalloid for hypotension or lactate = 4 mmol/L. This guideline has a rating of 'strong recommendation.'
The fluid requirements of patients were determined to be related to a patient’s caloric demand by Drs. Holliday and Segar in 1957. Since this time, their initial formula has been modified to provide clinicians with guidelines for administration of maintenance crystalloid fluids. The mass-based formula uses what is known as the “4-2-1” rule:
Example: 100kg patient: 20 kg (40 + 20 mL/hr) + 80 kg (80 mL/hr) = 140 mL/hr
Additional formulas for fluid administration have been developed for specific clinical scenarios (e.g., the Parkland Formula for fluid maintenance in burn patients).
Volume expansion with crystalloid fluids may cause iatrogenic fluid overload. The risk of this complication is particularly elevated in patients with impaired kidney function (acute kidney injury, chronic kidney disease, etc.) and these patients should, therefore, receive treatment with judicious use of intravenous fluids. Patients with congestive heart failure are at elevated risk for serious adverse effects of crystalloid fluid administration. Fluid overload can cause life-threatening pulmonary edema and the worsening of a diastolic or systolic heart failure, leading to end-organ damage or even death. It is vital for the clinician to monitor these patients carefully and to administer the minimum required volume to maintain volume homeostasis.
Normal Saline (0.9% Saline)
Normal saline has a higher concentration of chloride ions (154 mmol/L) than is found in human serum (98-106 mmol/L). With the administration of large volumes of normal saline, hyperchloremia occurs. While there is still some debate on the exact mechanism of this pH disturbance, the thinking is that the increase in chloride concentration adjusts the strong ion difference in plasma, resulting in more free water in the intravascular space. As a result, the hydrogen ion concentration in the serum would increase to maintain electrochemical neutrality. Excessive renal bicarbonate excretion can occur, resulting in metabolic acidosis. The dilution of serum bicarbonate through non-buffered crystalloids (e.g., normal saline) may also contribute to acidosis. Besides metabolic acidosis, clinical research has shown that high volumes of normal saline can cause hyperchloremia-induced renal afferent arteriole constriction, which can cause a decrease in the glomerular filtration rate.
Acetate buffered crystalloid solutions have been the subject of much debate in the medical literature. Studies performed on dogs have shown that even small volumes of acetate containing crystalloids can significantly increase the serum concentration of acetate to 10-40 times the physiologic level. Some suggest that acetate may potentiate hemodynamic instability via decreasing both myocardial contractility and blood pressure.
Unlike acetate buffered solutions, lactated crystalloid fluids have the potential to induce hyperglycemia. Lactate is a metabolically active compound that is utilized during the gluconeogenesis to produce glucose. Hence, excessive administration of lactated crystalloids may be of concern in diabetic patients.
Crystalloid fluids should not be administered to patients who are fluid-overloaded. Special care is prudent when administering fluids to patients with congestive heart failure or those with significant renal impairment (e.g., CKD-V dialysis-dependent patients).
Hypertonic saline is contraindicated in all clinical settings except in patients with severe hyponatremia and neurologic sequelae. Rapid correction of hyponatremia may cause central pontine myelinolysis, a devastating neurologic condition.
Hypotonic solutions are also contraindicated in patients with or at risk of developing cerebral edema.
Crystalloids containing potassium (Lactate ringers, Hartman’s solution, etc.) are relatively contraindicated in hyperkalemic patients since these may exacerbate their condition which in turn can lead to ventricular dysrhythmias.
Crystalloids containing dextrose (D5%W, D10%W, D5% 0.45% NS, etc.) should be avoided in patients with hyperglycemia.
Ringer Lactate solution contains calcium ions. Calcium can induce coagulation of the blood products in the IV tubing and therefore inhibit their effective delivery. In patients who require a blood transfusion, blood products should utilize a separate IV setup.
Patients should undergo assessment for signs and symptoms of dehydration and fluid overload. Indications that a patient may receive inadequate volume include elevated lactate and creatinine concentrations in the absence of an alternate cause. The urine output should be monitored. An ideal urine output target of 0.5 mL/kg/hr indicates adequate hydration but may not be useful to assess volume status in patients with renal impairment.
To monitor for fluid overload, patients at high risk of developing this complication should receive frequent re-evaluation. Providers should assess for new or worsening crackles. These sounds may indicate pulmonary edema secondary to volume overload. Additionally, any new or worsening peripheral edema in the extremities is also a potential indication of excessive crystalloid fluid administration.
In patients receiving hypertonic saline for severe hyponatremia with neurologic sequelae, frequent neurologic checks should be performed to assess for clinical improvement. Such monitoring can also help to identify worsening neurologic function as a potential indicator of cerebral edema or central pontine myelinolysis.
Patients receiving large volumes of crystalloid fluids should be monitored for electrolyte imbalances caused by crystalloid fluid administration.
IV fluids are commonly administered during resuscitation. Broadly, IV fluids can fall into two separate categories: crystalloids and colloids. In most clinical settings, crystalloids are the choice of fluid for many indications for fluid resuscitation, maintenance, or as a solvent for medication delivery.
The 2018 sepsis guidelines from the Surviving Sepsis Campaign have suggested the initiation of treatment with crystalloid fluids. However, they do not make recommendations regarding which fluid should is the best choice. According to their recommendations, fluids should be aggressively administered at a rate of 30 ml/kg in the first hour in a setting of hypotension or a lactate concentration greater than 4mmol/L [Evidence Level II].
Established guidelines for crystalloid fluid under various clinical conditions are not yet extant. The SMART and SMART-SURG trials demonstrated a decreased rate of AKI, but not overall survival among critically ill patients, who received Ringer's lactate, a balanced, lactate-buffered crystalloid over normal saline [Evidence Level I].
|||Boyd JH,Forbes J,Nakada TA,Walley KR,Russell JA, Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Critical care medicine. 2011 Feb [PubMed PMID: 20975548]|
|||Chesney CR, The maintenance need for water in parenteral fluid therapy, by Malcolm A. Holliday, MD, and William E. Segar, MD, Pediatrics, 1957;19:823-832. Pediatrics. 1998 Jul [PubMed PMID: 9651436]|
|||Eisenhut M, Causes and effects of hyperchloremic acidosis. Critical care (London, England). 2006 [PubMed PMID: 16834765]|
|||Chang R,Holcomb JB, Choice of Fluid Therapy in the Initial Management of Sepsis, Severe Sepsis, and Septic Shock. Shock (Augusta, Ga.). 2016 Jul [PubMed PMID: 26844975]|
|||Reddy S,Weinberg L,Young P, Crystalloid fluid therapy. Critical care (London, England). 2016 Mar 15 [PubMed PMID: 26976277]|
|||Fleischhacker E,Trentzsch H,Kuppinger D,Piltz S,Beyer F,Meigel F,Kammerer T,Rehm M,Hartl WH, Fluid resuscitation after severe trauma injury : U-shaped associations between tetrastarch dose and survival time or frequency of acute kidney failure. Medizinische Klinik, Intensivmedizin und Notfallmedizin. 2019 Nov 6 [PubMed PMID: 31696249]|
|||Gershkovich B,English SW,Doyle MA,Menon K,McIntyre L, Choice of crystalloid fluid in the treatment of hyperglycemic emergencies: a systematic review protocol. Systematic reviews. 2019 Sep 3 [PubMed PMID: 31481108]|
|||Duffy RA,Foroozesh MB,Loflin RD,Ie SR,Icard BL,Tegge AN,Nogueira JR,Kuehl DR,Smith DC,Loschner AL, Normal saline versus Normosol™-R in sepsis resuscitation: A retrospective cohort study. Journal of the Intensive Care Society. 2019 Aug [PubMed PMID: 31447915]|
|||Levy MM,Evans LE,Rhodes A, The Surviving Sepsis Campaign Bundle: 2018 update. Intensive care medicine. 2018 Jun [PubMed PMID: 29675566]|
|||Semler MW,Self WH,Wanderer JP,Ehrenfeld JM,Wang L,Byrne DW,Stollings JL,Kumar AB,Hughes CG,Hernandez A,Guillamondegui OD,May AK,Weavind L,Casey JD,Siew ED,Shaw AD,Bernard GR,Rice TW, Balanced Crystalloids versus Saline in Critically Ill Adults. The New England journal of medicine. 2018 Mar 1 [PubMed PMID: 29485925]|